Navigation Links
Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Date:8/23/2007

BOCA RATON, Fla., Aug. 23 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) today announced that Dr. Leslie Hudson, interim president and chief executive officer will participate in the Thomas Weisel Partners Healthcare Conference, to be held Sept. 5-7, 2007 at The Four Seasons Hotel in Boston. Dr. Hudson's presentation at the conference is scheduled for Thursday, Sept. 6 at 2:05 p.m. EDT. Dr. Hudson is also scheduled to participate in the Bear Stearns Healthcare Conference, to be held Sept. 10-11, 2007 at The Grand Hyatt Hotel in New York, where he is slated to present on Tuesday, Sept. 11 at 2:30 p.m. EDT.

At both conferences, Dr. Hudson will present a company overview including a review of Nabi's corporate strategy and an update of its clinical development programs. Webcasts of these presentations and webcast information can be accessed on the company's "Events and Webcasts" page at http://www.nabi.com.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and, in certain areas, market products that target serious medical conditions in the areas of hepatitis and transplants, gram positive bacterial infections and nicotine addiction. We are a vertically integrated company with sales of antibodies and other biologics, including Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], a pipeline of products in various stages of development, state-of-the-art manufacturing capability and a cash position that will allow us to advance our near-term pipeline products. The company operates through two strategic business units: Nabi Biologics and Nabi Pharmaceuticals. Nabi Biologics has responsibility for the company's protein and immunological products and development pipeline, including Nabi- HB. Nabi Pharmaceuticals is responsible for the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine) development programs. For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php. The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com.


'/>"/>
SOURCE Nabi Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017  BioGenex, a global leader in ... a novel system for quantitative immunohistochemistry (IHC). The ... of Rochester (NY, USA) and Konica-Minolta Inc. ( ... is able to accurately quantify the expression of ... growth factor receptor-2) in clinical samples. Quantitative IHC ...
(Date:2/16/2017)... Ann Arbor, MI (PRWEB) , ... February 16, 2017 , ... ... between 5:00-7:00 p.m. The event will be held at Avomeen Analytical Services (4840 ... hosted by a MichBio member organization. They provide an opportunity to interact with peers, ...
(Date:2/16/2017)... 16, 2017 Research and Markets ... Global Markets" report to their offering. ... ... biobrick parts, delivery plasmids, chassis organisms, synthetic cells, production ... genome editing, bioinformatics and specialty media) and enabled technologies ...
(Date:2/16/2017)... 16, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, today announced it ... and entered into a $5 million credit facility ... use the capital for general corporate purposes to ... the treatment of serious diseases treated by dermatologists. ...
Breaking Biology Technology:
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... NEW YORK , Jan. 24, 2017 /PRNewswire/ ... market study of the laboratory use of nuclear ... of 363 experienced end-users and profiled current practices, ... three years, as well as growth and opportunities. ... NMR, Instrument suppliers, NMR instruments, needs and innovation ...
(Date:1/19/2017)... 2017 Sensory Inc ., a ... for consumer electronics, and i nnerCore ... cybersecurity solutions, today announced a global partnership that ... worldwide to bolster security of data sensitive mobile ... authentication platforms they offer, innerCore now offers its ...
Breaking Biology News(10 mins):